Blocking gene expression to combat deadly fungal infection

June 15, 2017
Structure of a Bdf1 bromodomain bound to a chemical compound that blocks the growth of the fungus, Stopping Candida albicans, shown in the background. Credit: IlluScientia, University of Grenoble Alpes

Each year, invasive fungal infections sicken an estimated 2 million people worldwide and kill nearly 800,000 - but a team of international scientists have discovered a new approach for antifungal drug treatments.

Researchers from USC and France identified that a gene-regulating protein, Bdf1, is critical for the survival of the pathogenic , Candida albicans.

"We have shown that Bdf1 is an important new target for design," said Charles McKenna, a senior author of the study who is a professor of chemistry and pharmaceutical sciences in the USC Dornsife College of Letters, Arts and Sciences. "Our findings show that compounds that bind to this target will disrupt the growth of the fungus, opening the way to novel drug treatments for fungal disease."

The French scientists who led the study with McKenna were Jérôme Govin and Carlo Petosa, both at the University of Grenoble Alpes.

Rising health threat

The fungus, C. albicans, is an aggressive pathogen that in healthy individuals is normally held in check by the immune system. However, people with a weakened immune system, including patients who have cancer, HIV or autoimmune diseases, are susceptible to the infection, which can be life-threatening, McKenna said.

The team's findings, published on May 18 in the journal Nature Communications, may prove timely. Fungal infections such as candidiasis are increasingly resistant to drug treatments. Each year, an estimated 46,000 patients in the United States become infected with invasive candidiasis, according to the Centers for Disease Control and Prevention.

"When susceptible people develop candida infections, the fungus may enter the bloodstream. If treatment is unsuccessful, it has a very high mortality rate - in the 40 percent range," McKenna said. "We have a very limited number of drugs that are effective in treating such systemic infections. Unfortunately, like many other pathogens, C. albicans is increasingly resistant to the few available drugs, raising the stakes for patients, and fresh approaches are urgently needed."

Converging bioscience

McKenna noted that his team's discovery was made possible through convergent bioscience, an emerging fusion of multidisciplinary research to accelerate health-related discoveries from the bench to the bedside. By drawing from a diverse network of scientists, engineers and students, the USC Michelson Center for Convergent Bioscience program fosters biomedical discovery, innovation and real-world solutions to fast-track detection and cures for diseases ranging from microbial infections to Alzheimer's and cancer.

This fall, USC will open the hub for this new initiative, Michelson Hall - a 190,000 square-foot, high-tech research facility that is supported by a $50 million gift from retired spinal surgeon Gary K. Michelson and his wife, Alya Michelson. The facility will house the new USC Center for Drug Discovery with McKenna as its director.

Disrupting fungal gene expression

Many scientists are studying alternative approaches for possible treatments to diseases such as cancer by manipulating gene expression. The USC-Grenoble team is the first to prove that this approach is feasible to target .

"The idea is that if you shut down this specific protein, Bdf1, you totally disrupt the whole process of gene expression and it becomes impossible for the fungus to grow," said Govin. "If you knock out the gene that makes the Bdf1 protein, then the fungus doesn't grow. Moreover, the fungus is no longer virulent when injected into mice."

The challenge for the scientists was finding a compound that shut down the Bdf1 protein without mistakenly affecting any similar proteins in humans.

"Using a technique called X-ray crystallography, we showed that the fungal Bdf1 protein and corresponding human proteins are very different at the atomic level," said Petosa. "This showed that compounds could specifically inhibit the fungal without affecting the human bromodomain proteins."

By screening a large library of chemical compounds at the California Institute for Biomedical Research, the researchers have already identified one compound in particular that selectively inhibits Bdf1. The finding holds great promise for future drug development.

"It shows that a whole new class of antifungal drugs is possible," said McKenna.

Explore further: Novel algorithm predicts drug combinations to treat drug resistant fungal infections

More information: Flore Mietton et al, Selective BET bromodomain inhibition as an antifungal therapeutic strategy, Nature Communications (2017). DOI: 10.1038/ncomms15482

Related Stories

Novel algorithm predicts drug combinations to treat drug resistant fungal infections

July 14, 2016
Scientists have created an algorithm that can identify drug combinations to treat fungal infections that have become resistant to current drug treatments. This new study, published in PLOS Computational Biology, represents ...

Drug combinations a good approach for infectious fungus, research shows

February 6, 2015
Researchers at the University of Toronto have discovered that Candida albicans—a leading cause of potentially fatal hospital-acquired infections—rarely develops resistance to combination drug therapy and, when it becomes ...

Recommended for you

Exploring how herpes simplex virus changes when passed between family members

October 22, 2017
A new study explores how herpes simplex virus might change when passed from one individual to another, information that may prove useful in future development of therapeutics and vaccines. This rare glimpse into a transmission ...

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.